Depression Drugs Market

Depression Drugs Market Overview (2022 to 2032)

The global depression drugs market was valued at around US$ 15.3 Billion at the end of 2021. The market is projected to register a 3.7% CAGR and top a valuation of US$ 22.0 Billion by 2032.

The Rising prevalence of social anxiety and depression is expected to uplift the depression drugs market over the forecast period.

Depression is a mental disorder defined by a lack of pleasant feelings, a chronically depressed mood, and a wide range of cognitive, physical, behavioral, and emotional symptoms. It is diagnosed by determining the symptoms and reviewing the patient's medical history. The condition is then treated with antidepressants, which stabilize neurotransmitters like serotonin that function in the brain and regulate the patient's mood and emotions. These medications can help to lessen the symptoms of dysthymia, seasonal affective disorder, and anxiety.

Attributes	Details
Depression Drugs Market Value in 2021	US$ 15.3 Billion
Depression Drugs Market Value in 2032	US$ 22.0 Billion
Depression Drugs Market CAGR (2022 to 2032)	3.7%

What are the Major Drivers Boosting the Demand for Depression Drugs Market?

Depression is a prevalent mental disorder. According to estimates, 5% of the population worldwide experience depression. Depression is a major contributor to the overall global burden of disease, a primary cause of disability around the world, and it has an impact on the quality of life for those who are suffering from this condition. It is speculated that depression is more prevalent in women as compared to males. Over the forecast period, the market for depression drugs is anticipated to be driven by increased rates of social anxiety disorder, depression, and related illnesses.

The adoption rate is also rising as a result of the aging population, which is more vulnerable to certain medical problems. In the upcoming years, the depr4ession drugs market growth is predicted to be fueled by the development of novel therapies for the treatment of depression and the introduction of new antidepressants with negligible side effects and long-term outcomes.

The prevalence of mental health issues is rising, which is causing the market for treating depression to expand. These variables include demographic changes, environmental changes, mental stress, and more.

Which Region Shows Strong Growth Potential in the Depression Drugs Market?

The depression drugs market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America is the leading region in the global depression drugs market owing to the increasing number of people suffering from depression and rising campaigns about mental health led by profitable and non-profitable organizations.

The European depression drugs market is also expected to display lucrative growth in the projected years due to a more aware and concerned populace regarding anxiety and depressive disorders.

The East Asian region is predicted to show lucrative growth owing to the growing knowledge amongst the general population about mental disorders and mental well-being.

Who are the Key Players in the Depression Drugs Market?

Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 3.7% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Billion, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	Disorder Drug Class Distribution Channel Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany United Kingdom France Spain Italy China Japan South Korea Malaysia Singapore Australia New Zealand GCC Countries South Africa Israel
Key Players	Otsuka Pharmaceutical Pfizer Eli Lilly and Company AstraZeneca Novartis Bristol-Myers Squibb GlaxoSmithKline Takeda Pharmaceutical Company Allergan Johnson & Johnson Zhejiang NHU Company Ltd Sebela Pharmaceuticals
Customization	Available Upon Request

Key Segments Covered in the Depression Drugs Market Report

By Disorder:

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

By Drug Class:

• Atypical Antipsychotics
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Central Nervous System (CNS) Stimulants
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Serotonin Antagonist & Reuptake Inhibitors
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)